SEC Filings TLDR Banner

Stop wasting hours on dense SEC filings. Get AI-powered summaries of any SEC Filings in seconds. Understand key insights and risks, fast.

Currently we only process Form 8-K, 6-K, 3, 4, 144, Schedule 13D and Schedule 13G. We will support more forms in the future.

Filter by Form Type:
All346-K8-K10-Q144Schedule 13GSchedule 13G/ASchedule 13DSchedule 13D/A
Industry:Biotechnologyβœ•
Previous Page345678910Next Page
2026-09-09CYBN4Form 4 - Insider Purchase of 90,000 Common Shares by Chief Growth Officer Paul Glavine of Cybin Inc.MEDIUM
This Form 4 filing, submitted voluntarily by Paul Glavine, Chief Growth Officer of Cybin Inc. (CYBN), reports the acquisition of 90,000 common shares. The transaction occurred on August 31, 2026, at a price of $11.5853 per share, for a total value of approximately $1.04 million. Following this open-market purchase, Gla...
Biotechnologyacquired_p
2026-09-09CYBN4Cybin Inc. Executive Chair Eric H. L. So Voluntarily Files Form 4 After Purchasing 95,000 Common SharesMEDIUM
Cybin Inc. (NYSE American: CYBN) received a voluntary Form 4 from Eric H. L. So, the company's Executive Chair, who serves as both a director and officer. The filing reports that Mr. So acquired 95,000 Common Shares on September 1, 2026, at a price of $11.805 per share in an open-market purchase (transaction code "P"),...
Biotechnologyacquired_p
2026-09-09IPSC4Form 4: Century Therapeutics CTO/Mfg Officer Gregory Russotti Sells 534 Shares for RSU Tax Withholding
Century Therapeutics, Inc. (NASDAQ: IPSC) filed a Form 4 with the SEC reporting a transaction by Gregory Russotti, the company's Chief Technology and Manufacturing Officer. On September 8, 2026, Russotti sold 534 shares of Common Stock at a price of $2.05 per share, in a disposition (Code S) totaling approximately $1,0...
Small CapBiotechnologydisposed_s
2026-09-09IPSC4SEC Filing Summary for Century Therapeutics, Inc. - Form 4 FilingMEDIUM
This SEC filing (Form 4) details a transaction by Brent Pfeiffenberger, President and CEO of Century Therapeutics, Inc. On September 4, 2026, Mr. Pfeiffenberger disposed of 463 shares of Common Stock at a price of $2.11 per share. This transaction was related to tax withholding obligations in connection with the vestin...
Small CapBiotechnologydisposed_f
Previous Page345678910Next Page